Ocular Drug Delivery Technology Market Size & Share Analysis - Growth Trends And Forecast (2025 - 2032)

By Type;

Topical Delivery Systems, Injectable Delivery Systems, Implantable Drug Delivery Systems and Device-Assisted Delivery Systems

By Formulation;

Solutions, Suspensions, Ointments, Gels, Nanoparticles and Microspheres

By Route of Administration;

Intravitreal Injection, Subconjunctival Injection, Periocular Injection, Topical Instillation and Systemic Administration

By Application Area;

Glaucoma, Diabetic Retinopathy, Cataract Surgery, Macular Degeneration, Retinal Detachment and Dry Eye Syndrome

By End-User;

Hospitals, Ophthalmology Clinics, Ambulatory Surgical Centers (ASCs), Home Healthcare Settings and Research & Development Laboratories

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2022 - 2032)
Report ID: Rn915304257 Published Date: April, 2026 Updated Date: May, 2026

Ocular Drug Delivery Technology Market Overview

Ocular Drug Delivery Technology Market (USD Million)

In the year 2025, the Ocular Drug Delivery Technology Market was valued at USD 15,495.45 million in the year 2025. in the year 2025. The size of this market is expected to increase to USD 24,558.56 million by the year 2032, while growing at a Compounded Annual Growth Rate (CAGR) of 6.8%.


Ocular Drug Delivery Technology Market

*Market size in USD million

CAGR 6.8 %


Study Period2026 - 2032
Base Year2025
CAGR (%)6.8 %
Market Size (2025)USD 15,495.45 Million
Market Size (2032)USD 24,558.56 Million
Market ConcentrationMedium
Report Pages372
15,495.45
2025
24,558.56
2032

Major Players

  • Allergan AbbVie Inc
  • Novartis AG
  • Bausch Health Companies Inc
  • Ocular Therapeutix Inc
  • Santen Pharmaceutical Co Ltd
  • Alimera Sciences Inc
  • EyePoint Pharmaceuticals Inc
  • Clearside Biomedical Inc
  • Graybug Vision Inc
  • Envisia Therapeutics Inc
*Competitors List Not Exhaustive

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Ocular Drug Delivery Technology Market

Fragmented - Highly competitive market without dominant players


Ocular Drug Delivery Technology Market is gaining strong momentum as demand for innovative ophthalmic solutions rises. Around 63% of patients now prefer targeted delivery methods that enhance absorption and therapeutic results. This trend reflects a shift toward advanced systems designed to improve treatment precision and patient comfort.

Key Growth Drivers
The growing incidence of eye disorders and long-term vision problems is driving market expansion. Research highlights that 71% of patients with ocular conditions rely on effective and consistent drug delivery methods. Limitations in traditional techniques have accelerated the adoption of advanced delivery platforms, which ensure higher efficacy and reduce treatment challenges.

Innovation and Technology Trends
Emerging solutions such as nanocarriers, ocular implants, and sustained-release systems are reshaping the industry. These technologies have boosted drug retention and effectiveness by nearly 84%, while significantly improving patient adherence. The use of biocompatible materials and controlled mechanisms underscores the industry’s focus on safety and long-term performance.

Future Market Potential
The outlook for the market is highly positive, supported by continued research and growing adoption. Projections suggest that almost 78% of healthcare providers plan to expand use of advanced ocular delivery systems. With ongoing advancements in precision-based technologies, the Ocular Drug Delivery Technology Market is set to play a vital role in the future of eye care.

Ocular Drug Delivery Technology Market Key Takeaways

  • Ocular drug delivery technology is experiencing significant advancements, with the market projected to reach a valuation of USD 30.2 billion by 2034, advancing at a CAGR of 5.7% from 2024 to 2034 .

  • The increasing prevalence of age-related macular degeneration (AMD) is driving demand for innovative drug delivery systems, as this condition necessitates sustained and targeted therapies to manage retinal diseases effectively.

  • Nanotechnology-based formulations are gaining traction, with developments in nanoparticle carriers and microneedle systems enhancing drug bioavailability and enabling precise delivery to ocular tissues.

  • Hydrogel-based drug delivery systems are emerging as promising solutions, offering controlled and sustained release of therapeutics, thereby improving patient compliance and reducing the frequency of administration.

  • Suprachoroidal drug delivery is an innovative approach that involves delivering medication into the space between the sclera and choroid using microneedles, allowing for targeted treatment of posterior segment diseases with reduced invasiveness.

  • Regional growth is notable in the Asia-Pacific region, driven by increasing healthcare expenditure, a growing geriatric population, and rising awareness of advanced ocular drug delivery technologies .

  • Regulatory challenges remain a hurdle, as the approval process for new ocular drug delivery devices is often lengthy and complex, potentially delaying the introduction of innovative therapies to the market.

Ocular Drug Delivery Technology Market Recent Developments

  • In April 2024, leading companies in the Ocular Drug Delivery Technology Market developed nanoparticle-based delivery systems to enhance drug penetration and retention for treating posterior-segment eye disorders.

  • In September 2025, key players in the Ocular Drug Delivery Technology Market introduced smart drug-eluting contact lenses designed for sustained ocular therapy and improved patient compliance in chronic eye disease management.

Ocular Drug Delivery Technology Market Segment Analysis

In this report, the Ocular Drug Delivery Technology Market has been segmented by Type, Formulation, Route of Administration, Application Area, End-User, and Geography, covering the period from 2021 to 2031. This segmentation explores the advancements and growing adoption of ocular drug delivery technologies used to treat various eye diseases and conditions.

Ocular Drug Delivery Technology Market, Segmentation by Type

The Type segmentation categorizes the ocular drug delivery technologies based on their method of drug administration. Each type is designed to target specific eye tissues and provide effective delivery of therapeutic agents.

Topical Delivery Systems

Topical Delivery Systems are the most commonly used methods for ocular drug delivery. These systems include eye drops, ointments, and gels, providing direct application to the eye surface. They are ideal for treating surface-level eye conditions such as dry eye syndrome and conjunctivitis.

Injectable Delivery Systems

Injectable Delivery Systems involve administering drugs directly into the eye, often for treating more complex conditions like diabetic retinopathy and macular degeneration. These systems provide higher bioavailability and can deliver drugs more efficiently into the vitreous body.

Implantable Drug Delivery Systems

Implantable Drug Delivery Systems are used for long-term, controlled release of drugs into the eye. These systems are often used in treating chronic eye conditions that require continuous drug administration, such as glaucoma and macular degeneration.

Device-Assisted Delivery Systems

Device-Assisted Delivery Systems combine external devices, such as pumps or injectors, with drug formulations to facilitate more precise and controlled drug delivery. These devices are increasingly used for targeted treatment and improving patient compliance in long-term therapies.

Ocular Drug Delivery Technology Market, Segmentation by Formulation

The Formulation segmentation identifies the various forms in which ocular drugs are delivered. Each formulation type is designed to enhance the effectiveness of drug delivery and improve patient outcomes.

Solutions

Solutions are liquid formulations that can be easily instilled into the eye. They are widely used for their ease of application, particularly for treating surface-level conditions like conjunctivitis and dry eye syndrome.

Suspensions

Suspensions are drug formulations that contain solid particles suspended in liquid, offering a longer duration of action compared to solutions. They are often used for treating deeper eye tissues, such as in glaucoma management.

Ointments

Ointments are viscous, gel-like formulations that provide longer retention times on the eye's surface. They are used for treating conditions like dry eye syndrome, where prolonged contact with the eye surface is required for effective relief.

Gels

Gels are similar to ointments but are less viscous and easier to spread. Gels are commonly used in post-surgical care or in treating conditions like conjunctivitis and dry eye syndrome, as they offer sustained release of active ingredients.

Nanoparticles and Microspheres

Nanoparticles and Microspheres are cutting-edge formulations designed for controlled drug release. These technologies allow for sustained and targeted drug delivery to specific eye tissues, especially for the treatment of macular degeneration and retinal diseases.

Ocular Drug Delivery Technology Market, Segmentation by Route of Administration

The Route of Administration segmentation identifies the different pathways through which ocular drugs are delivered. Each route is chosen based on the specific condition being treated and the required therapeutic outcomes.

Intravitreal Injection

Intravitreal Injection is a highly effective route for delivering drugs directly into the vitreous body of the eye. This method is commonly used for conditions like macular degeneration and diabetic retinopathy, where targeted drug delivery is required.

Subconjunctival Injection

Subconjunctival Injection involves injecting the drug under the conjunctiva, the thin membrane covering the eye. This method is effective for delivering drugs to the anterior segment of the eye and is often used for treating glaucoma and other surface-level eye conditions.

Periocular Injection

Periocular Injection targets the tissues around the eye, such as the orbital fat or extraocular muscles. This method is commonly used for treating diseases of the posterior segment, such as retinal diseases, and allows for sustained drug release.

Topical Instillation

Topical Instillation is the most common route for delivering ocular drugs, typically in the form of eye drops. It is used for a variety of conditions, including glaucoma, dry eye syndrome, and other surface-level disorders, providing a non-invasive and easy method of administration.

Systemic Administration

Systemic Administration involves the drug entering the bloodstream and being distributed throughout the body, including the eye. This method is less common for ocular treatments but is used in certain systemic conditions affecting the eye, such as autoimmune diseases.

Ocular Drug Delivery Technology Market, Segmentation by Application Area

The Application Area segmentation identifies the main medical conditions treated using ocular drug delivery technologies. These application areas reflect the growing demand for advanced treatments in ophthalmology.

Glaucoma

Glaucoma is a leading cause of blindness, and ocular drug delivery technologies are essential for controlling intraocular pressure. Topical and injectable drugs are commonly used to treat glaucoma, with newer sustained-release systems offering improved patient compliance and more effective long-term management.

Diabetic Retinopathy

Diabetic Retinopathy is a common complication of diabetes that affects the retina. Ocular drug delivery systems, especially intravitreal injections, are used to deliver anti-VEGF therapies, preventing further damage to the retina and improving vision outcomes.

Cataract Surgery

Cataract Surgery is one of the most performed surgeries worldwide, and ocular drug delivery technologies are used for post-surgical treatment to reduce inflammation, prevent infection, and improve healing. Topical drops are commonly used in this context.

Macular Degeneration

Macular Degeneration is a leading cause of vision loss in older adults. Advanced ocular drug delivery technologies, including intravitreal injections, are used to deliver anti-VEGF therapies that help slow disease progression and preserve vision.

Retinal Detachment

Retinal Detachment is a medical emergency where the retina separates from the back of the eye. Treatment often involves surgery and drug delivery systems to reduce inflammation and prevent further retinal damage.

Dry Eye Syndrome

Dry Eye Syndrome is a condition characterized by insufficient tear production. Topical eye drops and gels are commonly used to treat this condition, improving tear film stability and providing relief from dryness and irritation.

Ocular Drug Delivery Technology Market, Segmentation by End-User

The End-User segmentation identifies the key healthcare settings where ocular drug delivery technologies are used. These end-users are essential for delivering effective treatments to patients with various eye diseases.

Hospitals

Hospitals are a primary end-user of ocular drug delivery technologies, particularly in surgical settings such as cataract and glaucoma surgeries. Hospitals provide advanced care and treatment for eye diseases, utilizing state-of-the-art drug delivery systems.

Ophthalmology Clinics

Ophthalmology Clinics specialize in treating various eye conditions and are key players in administering ocular drug delivery therapies. These clinics offer targeted treatments for diseases such as diabetic retinopathy and macular degeneration.

Ambulatory Surgical Centers (ASCs)

Ambulatory Surgical Centers (ASCs) are becoming increasingly popular for providing specialized eye treatments and surgeries. They use ocular drug delivery systems for outpatient procedures, offering convenience and cost-effective care for conditions like cataracts and glaucoma.

Home Healthcare Settings

Home Healthcare Settings are increasingly adopting ocular drug delivery systems for patient convenience and compliance. These settings are particularly suited for non-invasive therapies, such as topical eye drops for conditions like dry eye syndrome.

Research & Development Laboratories

Research & Development Laboratories play a key role in developing new ocular drug delivery technologies. These labs conduct studies to improve the efficacy, safety, and patient outcomes of ocular therapies.

Ocular Drug Delivery Technology Market, Segmentation by Geography

The Geography segmentation examines regional differences in market adoption, driven by factors such as healthcare infrastructure, regulatory environments, and disease prevalence.

Regions and Countries Analysed in this Report

Legend
North America
Rest of North America
Europe
Rest of Europe
Asia Pacific
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Africa
Latin America
Rest of Latin America

Rest of the World

North America

North America is the dominant region, driven by advanced healthcare infrastructure, high adoption of new technologies, and a large patient pool suffering from common eye diseases such as glaucoma and macular degeneration.

Europe

Europe shows steady demand, with well-established healthcare systems and a rising incidence of eye diseases. Strong government support for healthcare innovation in ophthalmology drives the market for ocular drug delivery technologies.

Asia Pacific

Asia Pacific is experiencing rapid market growth, particularly in China, India, and Japan, where rising healthcare access, aging populations, and increased awareness of eye diseases contribute to demand for ocular drug delivery systems.

Middle East & Africa

Middle East & Africa shows moderate growth, with urban areas in the Middle East leading the adoption of advanced ocular drug delivery technologies. The region is seeing increased investments in healthcare infrastructure.

Latin America

Latin America is seeing growing demand for ocular drug delivery systems, particularly in Brazil and Mexico, where healthcare access is improving and the prevalence of age-related eye conditions is rising.

Ocular Drug Delivery Technology Market Force

This report provides an in depth analysis of various factors that impact the dynamics of Ocular Drug Delivery Technology Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Comprehensive Market Impact Matrix

This matrix outlines how core market forces Drivers, Restraints, and Opportunities affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.

Market Forces ↓ / Impact Areas → Market Growth Rate Competitive Landscape Customer Behavior Regulatory Influence Innovation Potential
Drivers High impact (e.g., tech adoption, rising demand) Encourages new entrants and fosters expansion Increases usage and enhances demand elasticity Often aligns with progressive policy trends Fuels R&D initiatives and product development
Restraints Slows growth (e.g., high costs, supply chain issues) Raises entry barriers and may drive market consolidation Deters consumption due to friction or low awareness Introduces compliance hurdles and regulatory risks Limits innovation appetite and risk tolerance
Opportunities Unlocks new segments or untapped geographies Creates white space for innovation and M&A Opens new use cases and shifts consumer preferences Policy shifts may offer strategic advantages Sparks disruptive innovation and strategic alliances

Drivers, Restraints and Opportunity Analysis

Drivers:

  • Aging population increasing demand for ocular drug delivery technologies

  • Rising prevalence of ocular diseases worldwide - ocular drug delivery technology market is witnessing significant growth, primarily driven by the rising prevalence of ocular diseases worldwide. Conditions such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and others pose substantial challenges to eye health globally. As the aging population expands and lifestyle factors such as increased screen time become more prevalent, the incidence of these diseases is expected to rise further.

    In response to this growing demand, the ocular drug delivery technology market has seen a surge in innovation. Traditional methods of ocular drug administration, such as eye drops, face limitations such as low bioavailability and poor patient compliance. Consequently, there has been a shift towards the development of novel drug delivery systems that offer improved therapeutic outcomes and patient convenience. These systems include sustained-release implants, punctal plugs, and intravitreal injections, among others.

    Advancements in nanotechnology and biotechnology have revolutionized the field of ocular drug delivery. Nanoparticle-based formulations allow for targeted and sustained release of drugs to specific ocular tissues, enhancing efficacy while minimizing systemic side effects. Additionally, biodegradable implants offer a promising approach for long-term drug delivery, eliminating the need for frequent administrations and improving patient adherence to treatment regimens.

Restraints:

  • Stringent regulatory requirements for approval of ocular drug delivery systems

  • High cost associated with development and commercialization - ocular drug delivery technology market faces significant challenges due to the high costs associated with the development and commercialization of such technologies. Ocular drug delivery systems are designed to administer medications directly to the eye, offering targeted treatment for various ophthalmic conditions. However, the complex nature of the eye and the stringent regulatory requirements for ocular drugs pose substantial hurdles for companies developing these technologies. From conducting extensive preclinical studies to navigating through clinical trials, the process demands substantial financial investment, often running into millions of dollars.

    One major contributor to the high costs is the need for specialized research and development. Designing drug delivery systems that can effectively penetrate the ocular barriers while ensuring sustained release of the medication requires cutting-edge technology and expertise. Additionally, ensuring the safety and efficacy of these systems necessitates rigorous testing, further driving up development costs. Moreover, the regulatory pathway for ocular drugs is particularly challenging, requiring comprehensive data on safety, efficacy, and manufacturing processes to obtain approval from regulatory authorities such as the FDA and EMA.

    Commercialization of ocular drug delivery technologies also presents financial challenges. Once a technology has cleared regulatory hurdles, companies face the task of marketing and distributing their products. Establishing manufacturing facilities, building distribution networks, and promoting awareness among healthcare professionals and patients all require substantial investment. Furthermore, reimbursement issues can further complicate the commercialization process, as payers may be hesitant to cover the high costs associated with these specialized treatments.

Opportunities:

  • Technological advancements in drug delivery systems improving efficacy and patient compliance

  • Growing investment in research and development for novel ocular drug delivery technologies - ocular drug delivery technology market is experiencing significant growth, primarily driven by the increasing investment in research and development for novel ocular drug delivery technologies. With the prevalence of eye disorders such as glaucoma, macular degeneration, and diabetic retinopathy on the rise, there is a pressing need for effective and targeted delivery mechanisms for ocular drugs. Traditional methods like eye drops often suffer from low bioavailability and poor patient compliance, highlighting the demand for innovative solutions.

    Advancements in nanotechnology, microfabrication techniques, and biomaterials have paved the way for the development of sophisticated ocular drug delivery systems. These technologies offer precise control over drug release kinetics, enhanced tissue penetration, and improved patient comfort. Additionally, the integration of biocompatible materials into these delivery systems minimizes the risk of adverse reactions, making them suitable for long-term therapeutic applications.

    The growing aging population worldwide is fueling the demand for ocular drug delivery technologies. As individuals age, the prevalence of age-related eye diseases increases, driving the need for effective treatment options. Pharmaceutical companies and research institutions are thus ramping up their efforts to develop innovative delivery platforms that can address the unique challenges associated with ocular drug delivery.

Ocular Drug Delivery Technology Market Competitive Landscape Analysis

Ocular Drug Delivery Technology Market is characterized by rising competition among established pharmaceutical leaders and emerging biotech innovators. Companies are prioritizing strategies that emphasize sustained release mechanisms, non-invasive delivery, and patient compliance. Frequent collaboration and partnerships among research institutes, contract manufacturers, and developers are fostering market growth, with specialized solutions gaining significant attention in recent years.

Market Structure and Concentration

The market shows moderate concentration, where a few dominant players account for substantial percentages (%) of share. Strategic mergers and acquisitions have reinforced control for leading firms, while niche entrants pursue unique formulations. This balance between established leaders and new entrants supports healthy expansion, fostering competition while allowing technological advancements to shape future trajectories in ocular therapeutics.

Brand and Channel Strategies

Key companies employ diversified strategies across hospital, retail, and specialty pharmacies to ensure wide access to ocular treatments. Partnerships with distribution networks enhance expansion into emerging markets. Strong branding emphasizes innovation in delivery platforms, while digital promotion channels increasingly influence prescribing patterns. These channel-specific initiatives reinforce long-term growth prospects for dominant players.

Innovation Drivers and Technological Advancements

Continuous technological advancements in biodegradable implants, nanocarriers, and sustained-release systems drive competitiveness. Companies invest significant percentages (%) of revenue in R&D, resulting in patented solutions that strengthen intellectual property. Collaboration with academic institutions accelerates innovation, while regulatory approvals for novel platforms create momentum. These developments shape future strategies for maintaining market leadership.

Regional Momentum and Expansion

North America and Europe retain high percentages (%) of market presence due to advanced healthcare infrastructures and strong regulatory support. However, Asia-Pacific demonstrates rapid expansion fueled by increasing healthcare investments and partnerships with local manufacturers. Regional strategies prioritize affordability and accessibility, while multinational firms actively pursue collaborations to strengthen growth in underserved regions.

Future Outlook

The future outlook of this market highlights rising emphasis on personalized ocular therapies and integration of digital health monitoring. With percentages (%) of revenue directed toward innovation and pipeline development, competition will intensify. Strategic collaboration across sectors, growing regional expansion, and continuous technological advancements are expected to define the trajectory, shaping a highly progressive competitive environment.

Key players in Ocular Drug Delivery Technology Market include :

  • Allergan
  • Novartis AG
  • Bausch Health Companies Inc.
  • Ocular Therapeutix Inc.
  • Santen Pharmaceutical Co., Ltd.
  • Alimera Sciences Inc.
  • EyePoint Pharmaceuticals Inc.
  • Clearside Biomedical Inc.
  • Graybug Vision Inc.
  • Envisia Therapeutics Inc.
  • Eyenovia Inc.
  • Johnson & Johnson Vision
  • Laboratoires Théa
  • Ripple Therapeutics
  • AptarGroup Inc.

In this report, the profile of each market player provides following informatio

  • Market Share Analysis
  • Company Overview and Product Portfolio
  • Key Developments
  • Financial Overview
  • Strategies
  • Company SWOT Analysis
  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Type
    2. Market Snapshot, By Formulation
    3. Market Snapshot, By Route of Administration
    4. Market Snapshot, By Application Area
    5. Market Snapshot, By End-User
    6. Market Snapshot, By Region
  4. Ocular Drug Delivery Technology Market Forces
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Aging population increasing demand for ocular drug delivery technologies
        2. Rising prevalence of ocular diseases worldwide
      2. Restraints
        1. Stringent regulatory requirements for approval of ocular drug delivery systems
        2. High cost associated with development and commercialization
      3. Opportunities
        1. Technological advancements in drug delivery systems improving efficacy and patient compliance
        2. Growing investment in research and development for novel ocular drug delivery technologies
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Ocular Drug Delivery Technology Market, By Type, 2022 - 2032 (USD Million)
      1. Topical Delivery Systems
      2. Injectable Delivery Systems
      3. Implantable Drug Delivery Systems
      4. Device-Assisted Delivery Systems
    2. Ocular Drug Delivery Technology Market, By Formulation, 2022 - 2032 (USD Million)
      1. Solutions
      2. Suspensions
      3. Ointments
      4. Gels
      5. Nanoparticles
      6. Microspheres
    3. Ocular Drug Delivery Technology Market, By Route of Administration, 2022 - 2032 (USD Million)
      1. Intravitreal Injection
      2. Subconjunctival Injection
      3. Periocular Injection
      4. Topical Instillation
      5. Systemic Administration
    4. Ocular Drug Delivery Technology Market, By Application Area, 2022 - 2032 (USD Million)
      1. Glaucoma
      2. Diabetic Retinopathy
      3. Cataract Surgery
      4. Macular Degeneration
      5. Retinal Detachment
      6. Dry Eye Syndrome
    5. Ocular Drug Delivery Technology Market, By End-User, 2022 - 2032 (USD Million)
      1. Hospitals
      2. Ophthalmology Clinics
      3. Ambulatory Surgical Centers (ASCs)
      4. Home Healthcare Settings
      5. Research & Development Laboratories
    6. Ocular Drug Delivery Technology Market, By Geography, 2022 - 2032 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Allergan
      2. Novartis AG
      3. Bausch Health Companies Inc.
      4. Ocular Therapeutix Inc.
      5. Santen Pharmaceutical Co., Ltd.
      6. Alimera Sciences Inc.
      7. EyePoint Pharmaceuticals Inc.
      8. Clearside Biomedical Inc.
      9. Graybug Vision Inc.
      10. Envisia Therapeutics Inc.
      11. Eyenovia Inc.
      12. Johnson & Johnson Vision
      13. Laboratoires Théa
      14. Ripple Therapeutics
      15. AptarGroup Inc.
  7. Analyst Views
  8. Future Outlook of the Market